The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. (Q49105055)

18 February 2018

title

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. (English)

1 reference

18 February 2018

1 reference

1 reference

4

Nils Lycke

1 reference

18 February 2018

Xavier Saelens

7

object named as

Xavier Saelens

1 reference

18 February 2018

Walter Fiers

8

object named as

Walter Fiers

1 reference

18 February 2018

author name string

Marina De Filette

1

1 reference

18 February 2018

Anna Ramne

2

1 reference

18 February 2018

Ashley Birkett

3

1 reference

18 February 2018

Björn Löwenadler

5

1 reference

18 February 2018

Willy Min Jou

6

1 reference

18 February 2018

language of work or name

English

0 references

publication date

31 August 2005

1 reference

18 February 2018

published in

Vaccine

1 reference

18 February 2018

volume

24

1 reference

18 February 2018

issue

5

1 reference

18 February 2018

page(s)

544-551

1 reference

18 February 2018

Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Influenza: old and new threats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Mortality associated with influenza and respiratory syncytial virus in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Can needle-free administration of vaccines become the norm in global immunization?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Isolation and characterization of mouse nasal-associated lymphoid tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

What are the limits of adjuvanticity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Mucosal immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

A "universal" human influenza A vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Universal influenza A vaccine: optimization of M2-based constructs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Influenza virus M2 protein has ion channel activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Soluble recombinant influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Phylogenetic perspectives in innate immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Antibody response to the M2 protein of influenza A virus expressed in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.061

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.08.061

1 reference

18 February 2018

PubMed ID

16169634

1 reference

18 February 2018